DUBLIN--(BUSINESS WIRE)--The "Global DNA Sequencing Market: Growth, Trends & Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The Global DNA Sequencing Market is expected to witness a CAGR of 18.9% during the forecast period.
Certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis & drug discovery, and growing investment in R&D.
The technological advancements in sequencing, from 2D sequencing in the 1970's to DNA sequencing, has come a long way. In the recent years, platforms, such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. After the introduction of NGS technologies in 2005, they have had an incredible influence on genomic research.
Next-generation sequencing, currently, has its application in the diagnosis of a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. It is also used as a tool for noninvasive prenatal tests. NGS technologies have been used for standard sequencing applications, like genome sequencing and for novel applications that were previously unexplored by using Sanger sequencing.
Applications include whole genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses.
Key Market Trends
Next Generation Sequencing is Expected to Show Lucrative Growth Opportunity in the Platform Segment
Next Generation Sequencing can be of several types based on the technology. For example, the benefits offered by whole genome sequencing technique, such as ease of handling, affordability, and accuracy, are expected to boost their demand. Additionally, these tests are usually preferred by the market players as a single test, which is capable of providing information on multiple factors, such as virulence, serotype, and resistance.
FDA is applying NGS in innovative ways, which can help reduce foodborne illnesses and deaths. Isolation of pathogens from food or environmental samples may be compared to clinical isolates from patients. A reliable link between the two is made, which helps define the scope of a foodborne illness outbreak. Owing to such factors the concerned segment is expected to observe a steady growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
The North America dominated the global market studied, in 2018, owing to the increasing funding and support activities by the government and non-government entities, especially in the United States. By supporting genomics research, various government bodies, like NHGRI (National Human Genome Research Institute) have supported the work on sequencing of the human genome, and fund research on the genome's structure, function, and role in health and disease.
They also support studies on the ethical, legal, and social implications (ELSI) of genome research. The US National Human Genome Research Institute and the US National Academy of Medicine, organized 90 leaders in genomic medicine from the United States, and 25 other countries in Genomic Medicine Symposium in 2014, in order to identify opportunities for collaborations that promote the responsible practice of genomic medicine.
Competitive Landscape
The DNA Sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Inc., Merck KGaA, Pacific Biosciences of California, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., among others, hold the substantial market share in the DNA Sequencing market.
Key Topics Covered
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Technological Advancements in DNA Sequencing
4.2.2 Increasing Application in Clinical Diagnosis & Drug Discovery
4.2.3 Growing Investment in R&D
4.3 Market Restraints
4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals
4.3.2 Legal and Ethical Issues
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 Product Type
5.1.1 Instruments
5.1.2 Consumables (Kits, Reagents)
5.1.3 Others
5.2 Platform
5.2.1 Sanger
5.2.2 Next Generation Sequencing
5.2.3 qPCR
5.2.4 Others
5.3 Application
5.3.1 Diagnostics
5.3.2 Personalized Medicine
5.3.3 Others (Biomarkers, Forensics, Reproductive Health etc.)
5.4 End User
5.4.1 Hospitals and Healthcare Organizations
5.4.2 Academics and Research Institutions
5.4.3 Pharmaceutical and Biotechnology Companies
5.4.4 Others
5.5 Geography
5.5.1 North America
5.5.2 Europe
5.5.3 Asia Pacific
5.5.4 Middle East and Africa
5.5.5 South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies, Inc.
6.1.2 Bio-Rad Laboratories, Inc.
6.1.3 Danaher Corporation (Beckman Coulter, Inc.)
6.1.4 Eurofins Scientific
6.1.5 F. Hoffmann-La Roche
6.1.6 Illumina, Inc.
6.1.7 Merck KGaA
6.1.8 Pacific Biosciences of California, Inc.
6.1.9 PerkinElmer Inc.
6.1.10 Thermo Fisher Scientific, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/29pmu9
